A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia
NCT ID: NCT06821945
Last Updated: 2025-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2025-05-30
2027-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase IIA Study in Patients With Schizophrenia
NCT00686998
Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)
NCT00988728
A Study for Patients With Schizophrenia
NCT00520923
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
NCT05693935
Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia
NCT06253546
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gradual titration group
BR5402A
Subjects take the investigational products once a day
BR5402B
Subjects take the investigational products once a day
BR5402C
Subjects take the investigational products once a day
BR5402C-1
Subjects take the investigational products once a day
BR5402D
Subjects take the investigational products once a day
BR5402D-1
Subjects take the investigational products once a day
Conventional titration group
BR5402A-1
Subjects take the investigational products once a day
BR5402B-1
Subjects take the investigational products once a day
BR5402C
Subjects take the investigational products once a day
BR5402C-1
Subjects take the investigational products once a day
BR5402D
Subjects take the investigational products once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BR5402A
Subjects take the investigational products once a day
BR5402A-1
Subjects take the investigational products once a day
BR5402B
Subjects take the investigational products once a day
BR5402B-1
Subjects take the investigational products once a day
BR5402C
Subjects take the investigational products once a day
BR5402C-1
Subjects take the investigational products once a day
BR5402D
Subjects take the investigational products once a day
BR5402D-1
Subjects take the investigational products once a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with the duration of schizophrenia for more than 1 year at screening visit(Visit 1)
Exclusion Criteria
* Patients with a history of hospitalization for worsening schizophrenia within 12 weeks at screening visit(Visit 1)
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boryung Pharmaceutical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kyungbook National university hospital
Daegu, , South Korea
Hanyang University Guri Hospital
Guri-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Seung-hee Won
Role: primary
JoonHo Choi
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BR-OLZ-CT-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.